# Collegium Pharmaceutical, Inc: overview

COLL · Nasdaq · CIK 1267565 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/coll.md) · [Financials](/companies/coll/financials.md) · [Filings](/companies/coll/filings.md) · [Insiders](/companies/coll/insiders.md)

Latest reported revenue: [$199.9m](/filings/0001628280-26-053851.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-053851).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [159](/filings/0001628280-26-011992.md) | [182](/filings/0001628280-26-011992.md) | [178](/filings/0001628280-26-031697.md) | [188](/filings/0001628280-26-053851.md) | [209](/filings/0001628280-26-011992.md) | [205](/filings/0001628280-26-011992.md) | [194](/filings/0001628280-26-031697.md) | [200](/filings/0001628280-26-053851.md) |
| Gross margin | % | [60.8%](/filings/0001628280-26-011992.md) | [54.0%](/filings/0001628280-26-011992.md) | [54.8%](/filings/0001628280-26-031697.md) | [57.7%](/filings/0001628280-26-053851.md) | [61.7%](/filings/0001628280-26-011992.md) | [62.5%](/filings/0001628280-26-011992.md) | [60.6%](/filings/0001628280-26-031697.md) | [55.2%](/filings/0001628280-26-053851.md) |
| Operating margin | % | [21.9%](/filings/0001628280-26-011992.md) | [20.9%](/filings/0001628280-26-011992.md) | [12.2%](/filings/0001628280-26-031697.md) | [18.7%](/filings/0001628280-26-053851.md) | [29.7%](/filings/0001628280-26-011992.md) | [29.6%](/filings/0001628280-26-011992.md) | [16.0%](/filings/0001628280-26-031697.md) | [1.9%](/filings/0001628280-26-053851.md) |
| Net margin | % | [5.9%](/filings/0001628280-26-011992.md) | [6.9%](/filings/0001628280-26-011992.md) | [1.4%](/filings/0001628280-26-053851.md) | [6.4%](/filings/0001628280-26-053851.md) | [15.0%](/filings/0001628280-26-011992.md) | [8.3%](/filings/0001628280-26-011992.md) | [7.5%](/filings/0001628280-26-053851.md) | [(7.5%)](/filings/0001628280-26-053851.md) |
| Diluted EPS | $ per share | [0.27](/filings/0001628280-26-011992.md) | [0.36](/filings/0001628280-26-011992.md) | [0.07](/filings/0001628280-26-031697.md) | [0.34](/filings/0001628280-26-053851.md) | [0.84](/filings/0001628280-26-011992.md) | [0.46](/filings/0001628280-26-011992.md) | [0.40](/filings/0001628280-26-031697.md) | [(0.46)](/filings/0001628280-26-053851.md) |
| Free cash flow | $m | [(9.2) d](/filings/0001104659-25-107391.md) | [84.1 d](/filings/0001628280-26-011992.md) | [54.6](/filings/0001628280-26-031697.md) | [72.4 d](/filings/0001628280-26-053851.md) | [78.3 d](/filings/0001104659-25-107391.md) | [122 d](/filings/0001628280-26-011992.md) | [56.8](/filings/0001628280-26-031697.md) | [70.8 d](/filings/0001628280-26-053851.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [277](/filings/0001558370-24-001526.md) | [464](/filings/0001558370-25-001801.md) | [567](/filings/0001628280-26-011992.md) | [631](/filings/0001628280-26-011992.md) | [781](/filings/0001628280-26-011992.md) |
| Gross margin | % | [54.4%](/filings/0001558370-24-001526.md) | [45.2%](/filings/0001558370-25-001801.md) | [57.5%](/filings/0001628280-26-011992.md) | [59.8%](/filings/0001628280-26-011992.md) | [59.3%](/filings/0001628280-26-011992.md) |
| Operating margin | % | [6.4%](/filings/0001558370-24-001526.md) | [7.2%](/filings/0001558370-25-001801.md) | [29.5%](/filings/0001628280-26-011992.md) | [26.9%](/filings/0001628280-26-011992.md) | [23.0%](/filings/0001628280-26-011992.md) |
| Net margin | % | [25.8%](/filings/0001558370-24-001526.md) | [(5.4%)](/filings/0001558370-25-001801.md) | [8.5%](/filings/0001628280-26-011992.md) | [11.0%](/filings/0001628280-26-011992.md) | [8.1%](/filings/0001628280-26-011992.md) |
| Diluted EPS | $ per share | [1.86](/filings/0001558370-24-001526.md) | [(0.74)](/filings/0001558370-25-001801.md) | [1.29](/filings/0001628280-26-011992.md) | [1.86](/filings/0001628280-26-011992.md) | [1.73](/filings/0001628280-26-011992.md) |
| Free cash flow | $m | [102](/filings/0001558370-24-001526.md) | [123](/filings/0001558370-25-001801.md) | [274](/filings/0001628280-26-011992.md) | [203](/filings/0001628280-26-011992.md) | [328](/filings/0001628280-26-011992.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/coll/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $197.0m | 5,441,202 |  | Added +307,175 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $77.7m | 2,147,072 |  | Not compared |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $68.1m | 1,882,499 |  | Added +290,590 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $60.4m | 1,825,651 |  | Not compared |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $59.1m | 1,632,781 |  | Added +133,197 |
| [PRINCIPAL FINANCIAL GROUP INC](/funds/1126328.md) | 2026-06-30 | $59.1m | 1,632,360 |  | Added +337,332 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $55.3m | 1,528,881 |  | Added +104,337 |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $50.9m | 1,405,567 |  | Added +39,635 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $50.0m | 1,381,261 |  | Added +47,269 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $49.5m | 1,366,549 |  | Reduced −102,900 |

## Recent filings

[All 852 filings](/companies/coll/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-19 | 16:05 ET | [8-K](/filings/0001104659-26-116876.md) | 1.02 Termination of a material agreement | 0001104659-26-116876 |
| 2026-08-13 | 07:30 ET | [8-K](/filings/0001104659-26-095464.md) | 8.01 Other events | 0001104659-26-095464 |
| 2026-08-06 | 07:34 ET | [10-Q](/filings/0001628280-26-053851.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053851 |
| 2026-08-06 | 07:33 ET | [8-K](/filings/0001628280-26-053849.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001628280-26-053849 |
| 2026-06-30 | 16:05 ET | [8-K/A](/filings/0001104659-26-079323.md) | 9.01 Financial statements and exhibits | 0001104659-26-079323 |
| 2026-05-15 | 16:10 ET | [8-K](/filings/0001104659-26-062536.md) | 5.07 Shareholder vote results | 0001104659-26-062536 |
| 2026-05-12 | 07:43 ET | [8-K](/filings/0001104659-26-059018.md) | 2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-059018 |
| 2026-05-07 | 07:34 ET | [10-Q](/filings/0001628280-26-031697.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031697 |
| 2026-05-07 | 07:33 ET | [8-K](/filings/0001628280-26-031694.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-031694 |
| 2026-04-07 | 16:02 ET | [DEF 14A](/filings/0001628280-26-024063.md) | Proxy statement, period 2026-05-14 | 0001628280-26-024063 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-011992.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0e4d7eb6-0f33-4082-897a-6e581b09fa44)

## About the filer

- CIK: 1267565
- Tickers: COLL
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: VA
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:26 ET. No prices; not investment advice.